STARTUP COMPANIES CONFIRMED SO FAR


Vine Health: Georgina Kirby, Co-Founder & CTO 

Patient behaviours are the single biggest driver of quality of life and outcomes in cancer; yet patients struggle to cope with the complexity of medication and lifestyle behaviours involved in managing cancer. Vine Health is a digital ecosystem that combines behavioural science & AI to optimise care and increase survival of cancer patients. In empowering patients, the Vine Health platform gathers real-world patient-generated data that is crucial to pharmaceutical drug development, licensing and reimbursement.


FabricNano: Grant Aarons, CEO

FabricNano designs artificial cells that produce chemicals 100x faster, enabling manufacturers to scale output, reduce costs and discover new molecules.

 

Blazar: Dora Sabino, CEO

We are building a machine learning platform to predicit response to immunotherapies.

 

Nanovery: Mun Ching Lee, CEO

We are an AI-powered nanorobot platform for early cancer detection. We are building nanorobots that can capture circulating tumour DNA and emit a fluorescent signal, allowing point of care detection with just a blood sample. This is a game-changer in liquid biopsy as we are able to detect cancer in 1-2 hours compared to the 1-2 weeks turnaround of a standard liquid biopsy. We have an AI system to predict cancer progression, which enables us to generate a custom set of nanorobots to capture different biomarkers, enabling personalised treatment.

Panakeia Technologies: Pahini Pandya, CEO

Panakeia makes cancer diagnosis simpler, faster and cheaper by reducing the need for multiple tests. Pathologist assessment of biopsies is the gold standard for cancer diagnosis today. Complete diagnosis requires at least 4 additional tests done in separate labs. This takes 20 days and costs hospitals several thousand pounds. Panakeias' software uses deep-learning to provide pathologists with comprehensive diagnostic information from biopsy images they already have and fits into existing workflow. Patients can get diagnosis in 1 step, 2 days and at a fraction of the cost. We have partnerships with top cancer centres across 3 continents for data and trials of our patent-pending technology.

 


 

Antiverse: Rowina Westermeier, Director

Antiverse is developing a disruptive technology to predict antibodies against antigens using machine learning.

FindMeCure Ltd: Ralitsa Vaskova, Executive

FindMeCure is a young tech company with a clinical research background, working in the field of digital patient recruitment. 
Using our own intelligent algorithm, our online platform helps people all over the world find and join the most suitable for them clinical trials and at the same time helps companies to find easier and faster the most suitable patients for their clinical trials. 
We also have developed an Intelligence Data Platform combining real-time data, social listening and our proprietary algorithms to better plan and/or speed up clinical trials.

Quantum on Demand: Gunter Hermann, Co-Founder

Quantum on Demand (QoD) is a simulation-based and AI-driven research platform for the chemical and pharmaceutical industry. Powered by chemical and biochemical prediction models, we help our customers to accelerate the R&D of new pharmaceutical ingredients and novel materials - while increasing the cost-efficiency.

Lyfegen HealthTech AG: Nico Mros, Co-Founder and COO

Lyfegen is a healthcare technology company that has developed a ground-breaking solution to accelerate value-based healthcare. Its platform, Lyfevalue, collects, analyses & reconciles disparate healthcare data for the purpose of automating value-based healthcare contracting. The platform enables life science companies, national and private healthcare payers and healthcare providers to operationalise value-based healthcare strategies whilst benefiting from a single holistic solution for their value-based healthcare operations. In addition, the platform allows for personalised healthcare by enabling patient level pricing, fostering accelerated and facilitated access to innovative treatments for patients. 

Fast BT: Balendu Avvaru, CSO 

Fast BT is developing a revolutionary detection technology to enable the early detection of infectious diseases and biomarkers.





 


 Causaly: Yiannis Kiachopoulos, CEO 

Causaly is the world’s biggest Evidence Data Platform for BioMedicine. Our AI platform machine-reads 25,000,000 academic biomedical publications, adding 100,000 new publications every month. Within seconds it identifies and visualizes patterns, insights and relationships which leads to: Discoveries and insights from millions of articles that the human brain could easily miss, Better decision-making through improved understanding of patterns and relationships, Time- and cost savings by pre-reading and pre-qualifying millions of articles, Increased confidence in evidence scoping and improved article discovery due to premium content, Causaly is working with Industry, Governments and Academia to enable faster, higher quality and more transparent decision-making based on evidence.


InSilicoTrials Technologies: Luca Emili, CEO 

InSilicoTrials is the first cloud-based platform that provides healthcare companies and researchers with easy-to-use tools to perform computational modeling and simulation in pharmaceutical and medical devices development. We are working with FDA and EMA to make easier the development of new lifescience products

Lab Me Analytics: Anthony Close, CEO

Making Blood Testing Painless
At Home Testing, Simplified Results, & In-App Doctor Consults 
Say Goodbye to Needles and Waiting Rooms

Sens ID: Ronald Vos, BD 

Our products are the ideal solution for your R&D, validation of your instruments, external control, preparation of accreditation, ring trials, conformity assessment, as part of your diagnostic test kit, and much more. We offer you a range of human material in diverse product categories like gDNA, cfDNA/ctDNA, Plasma and FFPE with different genetic modifications like point mutations, insertions, deletions, amplifications and translocations. Additionally, we offer you a range of negative controls (certified DNA free) for liquid biopsy procedures.

Seqera Labs: Evan Floden Co-founder & CSO

We provide solutions to create, deploy and share massively scaleable workflows across clusters and clouds. Founded by the creators of Nextflow, Seqera Labs mission is to foster the adoption of professional open source software and strengthen the community effort around the Nextflow ecosystem. We enable teams to monitor, optimize and deploy pipelines in highly regulated environments, ensuring success at every step, from development to maintenance in production.

Arthronica: Letizia Gionfrida CEO

Arthronica is diagnostic medical tool that assists clinicians in the treatment auto-immune inflammatory conditions, C.R.Os in the running of clinical trials and Pharma companies in proving the effectiveness of their drugs. By utilising cutting edge artificial intelligence and ubiquitous consumer devices (smartphone/laptop) Arthronica provides precise longitudinal data on patients, enabling for first time, truly objective assessment,  treatment and recovery. Arthronica is a spinout company from Imperial College London, has received investment from Entrepreneurs First and Research England, and is a partner at JLabs in Beerse (the only European Johnson & Johnson innovation centre).

Entropica Labs: Tommaso Demarie, CEO

Entropica Labs is a spinoff of Singapore's Centre for Quantum Technologies, building a platform that uses machine learning on classical and quantum computing to analyse complex biological data. Entropica's mission is to generate new actionable biological insights from multi-omics datasets and phenotypic measurements, yielding a more robust drug discovery process to treat complex diseases. The vision is to reimagine how biological systems are simulated in silico, reducing the time and money spent testing and experimenting in the wet lab. The founding team has over 15 years of experience in quantum computing, distributed computing and machine learning

Pharmatrace:

PharmaTrace is a healthcare ecosystem built on blockchain. Leveraging A.I. & Machine Learning to connect complex data and create true digital transformation, we help pharmaceuticals and healthcare entities adopt blockchain technology to secure data, deploy smart contracts and AI/ML which enhance patient lifes hence better outcome- smart data usage, and transforming the medical chain environment.

FaunaBio: Ashley Zehnder Founder CEO

Fauna Bio is pushing beyond the classic mouse model to develop a cross-mammal drug discovery platform that takes advantage of 100 million years of evolution. 
The elephant’s resistance to cancer is a popular example of an animal adaptation that promotes health and longevity, but many others exist. Hibernating mammals begin to develop conditions similar to heart attack, stroke, diabetes, osteoporosis, and Alzheimer’s disease, but unlike humans, they are able to protect themselves from damage, or even subsequently cure themselves of these illnesses. With the recent dramatic drop in sequencing costs thousands of humans are being sequenced, but other mammal species remain an untapped reservoir of information that could be used to inspire therapeutic discovery.
 

Sano Genetics: Patrick Short, CEO

Sano Genetics is a platform for genomic and medical data with privacy and transparency at its core. Using a crowdsourcing model, we provide engaged patient cohorts and data for clinical trials recruitment and drug discovery.

 
 
 

Sign Up for Event Updates

Contact us

To sponsor or exhibit contact:
Harry Ludbrook
+44 (0)207 092 1049

Harry.Ludbrook@terrapinn.com


To speak:
Diana Georgi
+44 (0)20 7092 1075

Diana.georgi@terrapinn.com